# Prevention of COVID-19 Infection to Severe Pneumonia or ARDS

> **NCT04569227** · PHASE2 · UNKNOWN · sponsor: **Enzychem Lifesciences Corporation** · enrollment: 60 (estimated)

## Conditions studied

- Covid19 Pneumonia

## Interventions

- **DRUG:** EC-18
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04569227
- **Lead sponsor:** Enzychem Lifesciences Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-30
- **Primary completion:** 2021-09
- **Final completion:** 2021-11
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04569227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04569227, "Prevention of COVID-19 Infection to Severe Pneumonia or ARDS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04569227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*